- Home
- AUTL vs PLRX Comparison
AUTL vs PLRX Comparison
Compare AUTL & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- PLRX
- Stock Information
- Founded
- AUTL 2014
- PLRX 2015
- Country
- AUTL United Kingdom
- PLRX United States
- Employees
- AUTL N/A
- PLRX N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- PLRX Health Care
- Exchange
- AUTL Nasdaq
- PLRX Nasdaq
- Market Cap
- AUTL 590.8M
- PLRX 680.3M
- IPO Year
- AUTL 2018
- PLRX 2020
- Fundamental
- Price
- AUTL $2.17
- PLRX $11.37
- Analyst Decision
- AUTL Strong Buy
- PLRX Strong Buy
- Analyst Count
- AUTL 3
- PLRX 7
- Target Price
- AUTL $10.20
- PLRX $40.50
- AVG Volume (30 Days)
- AUTL 1.1M
- PLRX 485.5K
- Earning Date
- AUTL 03-13-2025
- PLRX 02-26-2025
- Dividend Yield
- AUTL N/A
- PLRX N/A
- EPS Growth
- AUTL N/A
- PLRX N/A
- EPS
- AUTL N/A
- PLRX N/A
- Revenue
- AUTL $10,091,000.00
- PLRX N/A
- Revenue This Year
- AUTL $851.83
- PLRX N/A
- Revenue Next Year
- AUTL $224.65
- PLRX N/A
- P/E Ratio
- AUTL N/A
- PLRX N/A
- Revenue Growth
- AUTL 82.71
- PLRX N/A
- 52 Week Low
- AUTL $2.07
- PLRX $10.22
- 52 Week High
- AUTL $7.37
- PLRX $18.00
- Technical
- Relative Strength Index (RSI)
- AUTL 41.81
- PLRX 44.60
- Support Level
- AUTL $2.11
- PLRX $10.35
- Resistance Level
- AUTL $2.26
- PLRX $11.07
- Average True Range (ATR)
- AUTL 0.12
- PLRX 0.61
- MACD
- AUTL 0.01
- PLRX 0.06
- Stochastic Oscillator
- AUTL 27.78
- PLRX 43.50
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.